mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis. - Wikidata - wikimedia - TriplyDB

mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.

mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.

http://www.wikidata.org/entity/Q33424013

about

Production of Mycophenolic Acid by Penicillium brevicompactum Using Solid State Fermentation.Effect of mechanistic target of rapamycin inhibitors on postrenal transplantation malignancy: A nationwide cohort study

P2860

Q50275839-03AB22F2-0318-42E0-AF61-CB191177EA0E Q58772577-9539093A-3C90-41DF-A7E5-07A32108F02B

P2860

mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.

http://www.wikidata.org/entity/Q33424013

description

2015 nî lūn-bûn

@nan

2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

mTOR inhibitor versus mycophen ...... t recipients: a meta-analysis.

@ast

mTOR inhibitor versus mycophen ...... t recipients: a meta-analysis.

@en

type

label

mTOR inhibitor versus mycophen ...... t recipients: a meta-analysis.

@ast

mTOR inhibitor versus mycophen ...... t recipients: a meta-analysis.

@en

prefLabel

mTOR inhibitor versus mycophen ...... t recipients: a meta-analysis.

@ast

mTOR inhibitor versus mycophen ...... t recipients: a meta-analysis.

@en

P1433

Q33424013-F5FE0370-6A72-4C0C-A0BE-170B7D01B26E

P1476

Q33424013-9C38FA7D-8027-4701-A062-6B9613650F93

P2093

Q33424013-40026477-C343-4D23-AA9C-3A47C7D9380D

Q33424013-5B80A4A9-C1C8-4964-A631-EBF6FF6BCBF8

Q33424013-6E9E8BDE-F370-4EDB-A25B-33A9856B6D91

Q33424013-854F62A0-297C-4D39-8B12-180DAAA170B5

Q33424013-E1F405B3-8B38-49BC-A9BF-8BF10B6E9C5D

Q33424013-E6B220AF-5B1C-45A0-A0A7-2EF83EC2B2CB

P2860

Q33424013-03F75C76-E797-49D8-BBC7-FAD3729A9407

Q33424013-127D4241-D60D-43D4-B98E-0D799430C08F

Q33424013-1987F4F5-B413-433E-8D50-948C84FA5DFC

Q33424013-1BA19977-4316-4025-BF68-2B99881D3F95

Q33424013-220F05C2-2118-4C77-93DE-5F352D0BD381

Q33424013-23A5FB91-86D3-49FC-85AF-ED1E4A88F2AB

Q33424013-2A12CF17-3651-4A0C-8F15-951B2F7C6062

Q33424013-450F5F08-A0AB-47EA-840F-3BF4AB48FF1F

Q33424013-524A5F68-FA6D-4AB7-8833-7A97C09AA94D

Q33424013-57C76332-A16C-4428-BFF3-A4E52A8311D5

P2888

Q33424013-01AC5F3A-E0FA-4D2F-A050-F1E4004744CB

P304

Q33424013-FD92B7E7-BD1B-4499-B4B6-F5716A40B26C

P31

Q33424013-116F8A5A-A147-47A4-BEB4-F7B7694DEAB5

Q33424013-a060503d-d0f3-42d1-abca-6ec22216d799

P356

Q33424013-7351BAEF-5161-4229-B01C-F1BB85A591E1

P478

Q33424013-87C343DD-E4A7-475F-9E4E-CA001893529E

P577

Q33424013-68969C15-DBDB-4A41-955F-524BB8D14DE5

P5875

Q33424013-A6293DB4-BE8A-450D-9D58-133A80617B3D

P6179

Q33424013-7BC98540-30E6-4AFB-9330-D1DA8435230D

P698

Q33424013-FB552E88-C3F4-4F6C-8684-4E4D59447D91

P921

Q33424013-F477C5A7-DFB9-41F9-B8BD-7A6B6C875734

P932

Q33424013-1E59B16A-A901-466D-B2EC-809570DFA9BB

P356

S12882-015-0078-5

P1433

P1476

mTOR inhibitor versus mycophen ...... t recipients: a meta-analysis.

@en

P2093

Jianghua Chen

http://www.w3.org/2001/XMLSchema#string

Shilong Xiang

http://www.w3.org/2001/XMLSchema#string

Xishao Xie

http://www.w3.org/2001/XMLSchema#string

Xiuxiu Lai

http://www.w3.org/2001/XMLSchema#string

Yan Jiang

http://www.w3.org/2001/XMLSchema#string

Zhangfei Shou

http://www.w3.org/2001/XMLSchema#string

P2860

Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials.

Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review.

Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature.

Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection.

Sirolimus is associated with new-onset diabetes in kidney transplant recipients.

Diagnosis and management of antibody-mediated rejection: current status and novel approaches.

Randomized trial of immunosuppressive regimens in renal transplantation.

Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus

P2888

s12882-015-0078-5

P304

91

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12882-015-0078-5

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

279729111

http://www.w3.org/2001/XMLSchema#string

P6179

1006961872

http://www.w3.org/2001/XMLSchema#string

P698

26126806

http://www.w3.org/2001/XMLSchema#string

P921

immunosuppression

P932

4486141

http://www.w3.org/2001/XMLSchema#string